006280.KS
GC Biopharma Corp.
KSC · Healthcare · Medical - Pharmaceuticals · KR
KRW 127,000.00
+0.00%Year over year
Reported trailing growth
- Revenue
- +9.7%
- EBITDA
- +21.0%
- EBIT
- -27.5%
- EPS
- —
- Free cash flow
- +183.1%
- Operating cash flow
- +485.3%
Forward estimates
Based on analyst estimates
- Revenue
- +5.6%
- EBITDA
- +23.4%
- EPS
- +179.1%
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- -6.0%
- EBIT
- -5.9%
- Net income
- +82.2%
- EPS
- +82.2%
- Free cash flow
- +3.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026